ATE145065T1 - Verfahren zur bestimmung der anwesenheit von diabetes assoziierten- oder inselzellen assoziierten antikörpers - Google Patents

Verfahren zur bestimmung der anwesenheit von diabetes assoziierten- oder inselzellen assoziierten antikörpers

Info

Publication number
ATE145065T1
ATE145065T1 AT92913743T AT92913743T ATE145065T1 AT E145065 T1 ATE145065 T1 AT E145065T1 AT 92913743 T AT92913743 T AT 92913743T AT 92913743 T AT92913743 T AT 92913743T AT E145065 T1 ATE145065 T1 AT E145065T1
Authority
AT
Austria
Prior art keywords
diabetes
glucose
insulin
gene
cells
Prior art date
Application number
AT92913743T
Other languages
English (en)
Inventor
Christopher B Newgard
Roger H Unger
John H Johnson
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE145065T1 publication Critical patent/ATE145065T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01001—Hexokinase (2.7.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
AT92913743T 1991-06-03 1992-06-02 Verfahren zur bestimmung der anwesenheit von diabetes assoziierten- oder inselzellen assoziierten antikörpers ATE145065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71003891A 1991-06-03 1991-06-03
US07/819,326 US5427940A (en) 1991-06-03 1992-01-13 Engineered cells producing insulin in response to glucose

Publications (1)

Publication Number Publication Date
ATE145065T1 true ATE145065T1 (de) 1996-11-15

Family

ID=27108362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92913743T ATE145065T1 (de) 1991-06-03 1992-06-02 Verfahren zur bestimmung der anwesenheit von diabetes assoziierten- oder inselzellen assoziierten antikörpers

Country Status (11)

Country Link
US (2) US5427940A (de)
EP (2) EP0590034B1 (de)
JP (2) JPH06508688A (de)
AT (1) ATE145065T1 (de)
AU (2) AU656213B2 (de)
CA (2) CA2103142A1 (de)
DE (1) DE69215092T2 (de)
DK (1) DK0590034T3 (de)
ES (1) ES2096084T3 (de)
GR (1) GR3022302T3 (de)
WO (2) WO1992021979A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744327A (en) * 1990-02-20 1998-04-28 Board Of Regents, The University Of Texas System Methods for producing insulin in response to non-glucose secretagogues
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5792656A (en) * 1991-06-03 1998-08-11 Board Of Regents, The University Of Texas System Methods of preparing genetically engineered cells that produce insulin in response to glucose
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
AU688304B2 (en) * 1993-02-09 1998-03-12 Monash University Methods for the diagnosis of diabetes and prediabetic conditions
US6008047A (en) * 1993-04-08 1999-12-28 Livercell L.L.C. Cell culturing method and medium
JP2813467B2 (ja) * 1993-04-08 1998-10-22 ヒューマン・セル・カルチャーズ・インコーポレーテッド 細胞培養法および培地
AU687836B2 (en) * 1993-06-28 1998-03-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes
EP0755268A1 (de) * 1994-04-11 1997-01-29 Baylor College Of Medicine Zusammensetzungen und verfahren zur behandlung von erkrankungen durch gentherapie
ES2156788B1 (es) * 1994-07-07 2002-02-01 Univ Barcelona Autonoma Genes quimericos que utilizan el cdna en orientacion antisentido del transportador de glucosa-2 (glut2) y animales transgenicos no humanos que expresan dichos genes quimericos para su utilizacion en el estudio de la diabetes mellitus y en el desarrollo de aproximaciones terapeuti
US5955579A (en) * 1995-05-09 1999-09-21 Strang Cancer Prevention Center Islet-specific homeoprotein and transcriptional regulator of insulin gene expression, HOXB13
US5891717A (en) * 1996-01-19 1999-04-06 Betagene, Inc. Methods and compositions for inhibiting hexokinase
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5854067A (en) * 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
US6352857B1 (en) 1997-01-21 2002-03-05 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
CA2318376A1 (en) * 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
AU3655399A (en) * 1998-04-20 1999-11-08 Vanderbilt University Neuroendocrine cells secreting insulin ans uses thereof
US6537806B1 (en) 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US8778899B2 (en) * 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6774120B1 (en) * 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6716824B1 (en) 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
JP2004530431A (ja) * 2001-06-08 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 免疫隔離装置内の細胞株活性を改善する方法
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
US20050014692A1 (en) * 2003-01-21 2005-01-20 Newgard Christopher B. Lactate dehydrogenase as a novel target and reagent for diabetes therapy
WO2004065552A2 (en) * 2003-01-21 2004-08-05 Duke University Cell-based therapies for diabetes mellitus and other glucose intolerant states
WO2005020977A1 (en) 2003-08-21 2005-03-10 Wisconsin Alumni Research Foundation Alpha-ketoglutarate potentiators of insulin secretion
EP1586650A1 (de) * 2004-04-16 2005-10-19 ProBioGen AG Eingriff in den Energiestoffwechsel von eukaryontenzellen zur Selektion und Expressionssteigerung
US20070128584A1 (en) * 2005-12-01 2007-06-07 Illani Atwater Method for isolation of cells
DK2185696T3 (en) 2007-08-10 2015-10-26 Univ Sydney Tech Cells genetically modified to include pancreatic glucokinase, and uses thereof
WO2012170531A1 (en) 2011-06-07 2012-12-13 Wisconsin Alumni Research Foundation Hepatocyte based insulin gene therapy for diabetes
CA2915143C (en) 2013-06-13 2021-08-03 Orgenesis Ltd. Cell populations, methods of transdifferentiation and methods of use thereof
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3635106A4 (de) 2017-05-08 2021-01-06 Orgenesis Ltd. Transdifferenzierte zellpopulationen und verfahren zur verwendung davon
US20210290821A1 (en) * 2018-07-27 2021-09-23 Washington University Cell-embedded vascular graft for transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757169A1 (de) * 1977-12-22 1979-07-05 Hoechst Ag Verfahren zur gewinnung insulin produzierender tierischer zellen
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
WO1987005929A1 (en) * 1986-04-01 1987-10-08 Genelabs Incorporated Immortalized cells which produce tissue-specific products
EP0561140B1 (de) * 1986-05-20 2002-01-30 The General Hospital Corporation Verfahren zur pharmakokinetischen Studie der Insulin-Expression mit nicht-menschlichem Transgen-Säugetier
IL85203A0 (en) * 1988-01-26 1988-07-31 Yeda Res & Dev Assay for diabetes
ES2077670T3 (es) * 1988-12-13 1995-12-01 Univ Florida Metodos y composiciones que sirven para la deteccion precoz y el tratamiento de la diabetes mellitus dependiente de la insulina.
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5002661A (en) * 1989-08-25 1991-03-26 W. R. Grace & Co.-Conn. Artificial pancreatic perfusion device
GB8928884D0 (en) * 1989-12-21 1990-02-28 Feldmann Marc Transformed cell lines
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5175085A (en) * 1990-02-20 1992-12-29 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing autoimmune insulin dependent diabetes mellitus
EP0543945B1 (de) * 1990-08-17 1996-10-16 The University Of Florida Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes
WO1995005452A2 (en) * 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
FR2710654B1 (fr) * 1993-09-30 1995-12-22 Maryam Asfari Nouvelles lignées de cellules sécrétrices d'insuline, leurs procédés d'obtention par voie de manipulation génétique et leur utilisation chez des sujets diabétiques sous forme protégée.

Also Published As

Publication number Publication date
AU2191892A (en) 1993-01-08
US5747325A (en) 1998-05-05
JPH06508688A (ja) 1994-09-29
EP0590034A1 (de) 1994-04-06
DK0590034T3 (da) 1996-11-25
ES2096084T3 (es) 1997-03-01
CA2103365A1 (en) 1992-12-04
US5427940A (en) 1995-06-27
DE69215092D1 (de) 1996-12-12
GR3022302T3 (en) 1997-04-30
AU656213B2 (en) 1995-01-27
JPH06508266A (ja) 1994-09-22
CA2103142A1 (en) 1992-12-04
WO1992021756A1 (en) 1992-12-10
AU656613B2 (en) 1995-02-09
WO1992021979A1 (en) 1992-12-10
AU2190792A (en) 1993-01-08
EP0590034B1 (de) 1996-11-06
EP0587771A1 (de) 1994-03-23
DE69215092T2 (de) 1997-05-22

Similar Documents

Publication Publication Date Title
ATE145065T1 (de) Verfahren zur bestimmung der anwesenheit von diabetes assoziierten- oder inselzellen assoziierten antikörpers
DK15182A (da) Fremgangsmaade til fremstilling af recombinant-dna
Lehmann et al. Bubble free cell culture aeration with porous moving membranes.
KR840008695A (ko) 효모표현 시스템에 α-인자 서열을 이용하는 방법
ATE127658T1 (de) Massenherstellung in flüssiger kultur von insektentötenden nematoden.
Truskey Advancing cardiovascular tissue engineering
AU2020314137A1 (en) Cell culture method and application thereof based on high-density and continuous inoculation
CN101302517B (zh) 人白细胞介素7在真核宿主中表达的方法
CN102268402A (zh) 无血清培养基及cho细胞中高效表达促红素的培养方法
Rechnitz The development of biocatalytic membrane electrodes
Gramer et al. Comparison of cell growth in T-flasks, in micro hollow fiber bioreactors, and in an industrial scale hollow fiber bioreactor system
CN102776260B (zh) 一种高效表达重组人凝血八因子的方法
Lipman et al. Hollow fibre bioreactors: an alternative to murine ascites for small scale (< 1 gram) monoclonal antibody production
ATE85644T1 (de) Verfahren zur erhoehung von gen-expression.
Bechler et al. Culture of hybridoma and Friend leukemia virus transformed cells in microgravity. Spacelab IML-1 mission
Willard et al. Simultaneous indirect activity measurements of GH and PRL genes in the same, living mammosomatotrope
DE59813558D1 (de) Fermentationsverfahren mit kontinuierlicher massenkultivierung von ciliaten (protozoa) zur produktion biogener wertstoffe
AU581819B2 (en) Process for the immortalization of human and animal cells
LaPorte et al. Long term shear effects on a hybridoma cell line by dynamic perfusion devices
Croughan et al. From microcarriers to hydrodynamics: Introducing engineering science into animal cell culture
Werner et al. Fermentation with immobilized cell cultures.
NZ515762A (en) Method of producing a heparin-binding protein by expressing it in a mammalian cell that can be cultured in anaerobic conditions
Saltis et al. Multiple growth abnormalities in vascular smooth muscle from spontaneously hypertensive rats.
Axelsson BIO Technica'85 Hannover
Ramasubramanyan Modeling and analysis of bioreactor designs for the culturing of immobilized and suspended animal/insect cells.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee